1DJJ - Header Asymmetric Unit

HEADER OXIDOREDUCTASE/OXIDOREDUCTASE INHIBITOR 03-DEC-99 1DJJ

TITLE KNOWLEDGE BASED MODEL OF THE MEMBRANE PROTEIN, TITLE 2 CYCLOOXYGENASE (COX-1) AND NSAID COMPLEX

COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: CYCLOOXYGENASE; COMPND 5 EC: 1.14.99.1

SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: OVIS ARIES; SOURCE 3 ORGANISM_COMMON: SHEEP; SOURCE 4 ORGANELLE: SEMINAL VESICLE; SOURCE 5 SECRETION: SEMEN

KEYWDS NSAID-COX-1 COMPLEX, ANTIINFLAMMATORY, ANTIPYRETIC AGENTS, KEYWDS 2 PROTEIN-INHIBITOR COMPLEX

EXPDTA THEORETICAL MODEL

AUTHOR A.BANERJEE,A.K.PAL,S.BHATTACHARYYA

REVDAT 1 17-DEC-99 1DJJ 0

JRNL AUTH A.BANERJEE,A.K.PAL,S.CHAKRABORTY,S.GHOSH, JRNL AUTH 2 S.BHATTACHARYYA JRNL TITL STRUCTURAL BASIS OF ANTIINFLAMMATORY ACTIVITY OF JRNL TITL 2 N-PHENYL DICHLOROACETANILIDE. A KNOWLEDGE BASED JRNL TITL 3 MOLECULAR MODELLING STUDY OF COMPLEX OF COX-1 WITH JRNL TITL 4 N-PHENYL DICHLOROACETANILIDE (NSAID) USING THE JRNL TITL 5 X-RAY STRUCTURE OF COX-1-ASPIRIN COMPLEX. JRNL REF TO BE PUBLISHED JRNL REFN

REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH A.K.PAL,A.K.BERA,A.BANERJEE REMARK 1 TITL CRYSTAL STRUCTURE OF REMARK 1 TITL 2 N-PHENYLDICHLOROACETAMIDE,C8H7NOCL2 REMARK 1 REF ZEITS.FUR.KRISTALLOGRAPHIE V. 213 249 1998 REMARK 1 REFERENCE 2 REMARK 1 AUTH P.J.LOLL,D.PICOT,R.M.GARAVITO REMARK 1 TITL THE STRUCTURAL BASIS OF ASPIRIN ACTIVITY INFERRED REMARK 1 TITL 2 FROM THE CRYSTAL STRUCTURE OF INACTIVATED REMARK 1 TITL 3 PROSTAGLANDIN H2 SYNTHASE REMARK 1 REF NAT.STRUCT.BIOL. V. 2 637 1995 REMARK 1 REFN ASTM NSBIEW US ISSN 1072-8368 REMARK 1 REFERENCE 3 REMARK 1 AUTH D.PICOT,P.J.LOLL,R.M.GARAVITO REMARK 1 TITL THE X-RAY CRYSTAL STRUCTURE OF THE MEMBRANE REMARK 1 TITL 2 PROTEIN PROSTAGLANDIN H2 SYNTHASE-1 REMARK 1 REF NATURE V. 367 243 1994 REMARK 1 REFN ASTM NATUAS UK ISSN 0028-0836 REMARK 1 REFERENCE 4 REMARK 1 AUTH P.J.LOLL,D.PICOT,O.EKABO,R.M.GARAVITO REMARK 1 TITL SYNTHESIS AND USE OF IODINATED NONSTEROIDAL REMARK 1 TITL 2 ANTIINFLAMMATORY DRUG ANALOGS AS CRYSTALLOGRAPHIC REMARK 1 TITL 3 PROBES OF THE PROSTAGLANDIN H2 SYNTHASE REMARK 1 TITL 4 CYCLOOXYGENASE ACTIVE SITE REMARK 1 REF BIOCHEMISTRY V. 35 7330 340 REMARK 1 REFN ASTM BICHAW US ISSN 0006-2960 REMARK 1 REFERENCE 5 REMARK 1 AUTH R.G.KURUMBALI,A.M.STEVENS,J.K.GIERSE,J.J.MCDONALD, REMARK 1 AUTH 2 R.A.STEGEMAN REMARK 1 TITL STRUCTURAL BASIS FOR SELECTIVE INHIBITION OF REMARK 1 TITL 2 CYCLOOXYGENASE-2 BY ANTI- INFLAMMATORY AGENTS REMARK 1 REF NATURE V. 384 644 1996 REMARK 1 REFN ASTM NATUAS UK ISSN 0028-0836 REMARK 1 REFERENCE 6 REMARK 1 AUTH T.SHIMOKAWA,R.J.KULMACZ,D.L.DEWITT,W.L.SMITH REMARK 1 TITL TYROSIN385 OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE REMARK 1 TITL 2 IS REQUIRED FOR CYCLOOXYGENASE CATALYSIS REMARK 1 REF J.BIOL.CHEM. V. 265 20073 1990 REMARK 1 REFN ASTM JBCHA3 US ISSN 0021-9258 REMARK 1 REFERENCE 7 REMARK 1 AUTH G.J.ROTH,E.T.MACHUGA,J.OZOLS REMARK 1 TITL ISOLATION AND COVALENT STRUCTURE OF THE REMARK 1 TITL 2 ASPIRIN-MODIFIED ACTIVE-SITE REGION OF REMARK 1 TITL 3 PROSTAGLANDIN SYNTHASE REMARK 1 REF BIOCHEMISTRY V. 22 4672 1983 REMARK 1 REFN ASTM BICHAW US ISSN 0006-2960 REMARK 1 REFERENCE 8 REMARK 1 AUTH H.H.RUF,U.RAAB-BRILL,C.BLAU REMARK 1 TITL A MODEL FOR THE CATALYTIC MECHANISM OF REMARK 1 TITL 2 PROSTAGLANDIN ENDOPEROXIDE SYNTHASE REMARK 1 REF BIOCHEM.SOC.TRANS. V. 21 739 1993 REMARK 1 REFN ASTM BCSTB5 UK ISSN 0300-5127

REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE.

REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : NULL REMARK 3 AUTHORS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL

REMARK 4 REMARK 4 1DJJ COMPLIES WITH FORMAT V. 2.3, 09-JULY-1998

REMARK 7 REMARK 7 RECENTLY POTENTIAL MEMBRANE PROTEIN INHIBITORS ARE REMARK 7 IN THE FOCUS FOR THEIR IMPORTANT APPLICATION REMARK 7 IN MEDICAL SECTORS. A CLASS OF DRUGS WITH REMARK 7 EXCELLENT MECHANISM FOR FIGHTING DISEASES HAS BREATHED REMARK 7 HOPE INTO MEDICAL RESEARCH. THESE DRUGS, MEMBRANE PROTEIN REMARK 7 INHIBITORS, ARE BEING USED AS ANTIPYRETIC AND ANTI- REMARK 7 INFLAMMATORY AGENTS IN VARIOUS INFLAMMATION STATE. IN REMARK 7 ABSENCE OF ANY EXPERIMENTAL STRUCTURAL DATA FOR N-PHENYL REMARK 7 DICHLOROACETANILIDE, AN ANALOG OF ACETANILIDE, COMPLEXED REMARK 7 WITH COX-1,MOLECULAR MODELLING CAN BE USED TO IDENTIFY REMARK 7 CONSERVED SIGNATURES OF BIOLOGICALLY IMPORTANT REMARK 7 CONFORMATIONS AND MOTIFFS, RELEVANT IN BIOLOGICAL REMARK 7 FUNCTIONS.

REMARK 8 REMARK 8 CLINICALLY POTENTIAL INHIBITOR, ACETANILIDE, REMARK 8 ACETAMINOPHEN ETC, HAS BEEN MODELLED AGAINST X-RAY REMARK 8 STRUCTURE OF NSAID-COX1 (1PTH.ENT). THE INHIBITOR IS A REMARK 8 SMALL MOLECULE CONSISTING OF 12 ATOMS WITH ONE CARBONYL REMARK 8 OXYGEN. THE INHIBITOR WHOSE X-RAY STRUCTURE HAS BEEN REMARK 8 DONE(REF NO.1), HAS BEEN MODELLED IN THE COMPLEXED STATE REMARK 8 BY DOCKING THE INHIBITOR TO COX-1 AND SUBSEQUENTLY BY REMARK 8 ENERGY MINIMISATION OF THE COMPLEX.

REMARK 9 REMARK 9 DIFFERENCE ACCESSIBLE SURFACE AREA (DASA) STUDY OF COX-1 REMARK 9 WITH AND WITHOUT THE INHIBITOR REMARK 9 (N-PHENYL DICHLOROACETANILIDE 1) SHOW THAT THE RESIDUES REMARK 9 AT THE ACTIVE SITE OF COX-1 - ARGININE (ARG 120) REMARK 9 AND TYROSINE (TYR355) - INTERACT WITH THE INHIBITOR. REMARK 9 DASA STUDY SUGGESTS HOW BINDING AFFINITY REMARK 9 AND MOLECULAR RECOGNITION AFFECT STRUCTURE-FUNCTION REMARK 9 ACTIVITY IN THE SYSTEM.

REMARK 10 REMARK 10 MOLECULAR CONFORMATIONS OF THE INHIBITOR REMARK 10 (N-PHENYL DICHLOROACETANILIDE) FALL IN THE ALLOWED REGION REMARK 10 OF STEREOCHEMISTRY AND THE CONFORMATIONS OF COX-1 EITHER REMARK 10 FALL IN THE ALLOWED REGION OF RAMACHANDRAN PLOT OR IN THE REMARK 10 EXTENDED ALLOWED REGION OF THE RAMACHANDRAN PLOT REMARK 10 SIGNIFYING THAT THE COMPLEX IS OF THE CORRECT AND SIMILAR REMARK 10 CONFORMATION AS THAT OF REPORTED COX1-NSAID COMPLEX.

REMARK 11 REMARK 11 MODEL BUILDING OF THE INHIBITOR IN THE COMPLEXED STATE REMARK 11 WAS PERFORMED ON A SILICON GRAPHICS IRIS INDIGO REMARK 11 WORKSTATION USING THE COMMERCIAL SOFTWARE PACKAGES REMARK 11 INSIGHT-II(BIOSYM TECHNOLOGY,SAN DIEGO,CA).

REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 13-DEC-1999. REMARK 100 THE RCSB ID CODE IS RCSB010132.

REMARK 220 REMARK 220 EXPERIMENTAL DETAILS REMARK 220 EXPERIMENT TYPE : THEORETICAL MODELLING REMARK 220 REMARK 220 REMARK: NULL

REMARK 225 REMARK 225 THEORETICAL MODEL REMARK 225 THE COORDINATES IN THIS ENTRY REPRESENT A MODEL STRUCTURE. REMARK 225 PROTEIN DATA BANK CONVENTIONS REQUIRE THAT CRYST1 AND REMARK 225 SCALE RECORDS BE INCLUDED, BUT THE VALUES ON THESE REMARK 225 RECORDS ARE MEANINGLESS.

REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ALA A 25 REMARK 465 ASP A 26 REMARK 465 PRO A 27 REMARK 465 GLY A 28 REMARK 465 ALA A 29 REMARK 465 PRO A 30 REMARK 465 ALA A 31 REMARK 465 PRO A 32 REMARK 465 ASP A 584 REMARK 465 PRO A 585 REMARK 465 ARG A 586 REMARK 465 GLN A 587 REMARK 465 GLU A 588 REMARK 465 ASP A 589 REMARK 465 ARG A 590 REMARK 465 PRO A 591 REMARK 465 GLY A 592 REMARK 465 VAL A 593 REMARK 465 GLU A 594 REMARK 465 ARG A 595 REMARK 465 PRO A 596 REMARK 465 PRO A 597 REMARK 465 THR A 598 REMARK 465 GLU A 599 REMARK 465 LEU A 600

REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI REMARK 500 NE2 HIS A 388 FE HEM 601 2.10 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),F6.3) REMARK 500 REMARK 500 EXPECTED VALUES: ENGH AND HUBER, 1991 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 HIS A 388 CE1 HIS A 388 NE2 0.149

REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1PTH RELATED DB: PDB REMARK 900 1PTH CONTAINS THE SAME PROTEIN COMPLEXED WITH ASPIRIN

DBREF 1DJJ A 1 576 UNP P05979 PGH1_SHEEP 25 600

SEQRES 1 A 576 ALA ASP PRO GLY ALA PRO ALA PRO VAL ASN PRO CYS CYS SEQRES 2 A 576 TYR TYR PRO CYS GLN HIS GLN GLY ILE CYS VAL ARG PHE SEQRES 3 A 576 GLY LEU ASP ARG TYR GLN CYS ASP CYS THR ARG THR GLY SEQRES 4 A 576 TYR SER GLY PRO ASN CYS THR ILE PRO GLU ILE TRP THR SEQRES 5 A 576 TRP LEU ARG THR THR LEU ARG PRO SER PRO SER PHE ILE SEQRES 6 A 576 HIS PHE LEU LEU THR HIS GLY ARG TRP LEU TRP ASP PHE SEQRES 7 A 576 VAL ASN ALA THR PHE ILE ARG ASP THR LEU MET ARG LEU SEQRES 8 A 576 VAL LEU THR VAL ARG SER ASN LEU ILE PRO SER PRO PRO SEQRES 9 A 576 THR TYR ASN ILE ALA HIS ASP TYR ILE SER TRP GLU SER SEQRES 10 A 576 PHE SER ASN VAL SER TYR TYR THR ARG ILE LEU PRO SER SEQRES 11 A 576 VAL PRO ARG ASP CYS PRO THR PRO MET GLY THR LYS GLY SEQRES 12 A 576 LYS LYS GLN LEU PRO ASP ALA GLU PHE LEU SER ARG ARG SEQRES 13 A 576 PHE LEU LEU ARG ARG LYS PHE ILE PRO ASP PRO GLN GLY SEQRES 14 A 576 THR ASN LEU MET PHE ALA PHE PHE ALA GLN HIS PHE THR SEQRES 15 A 576 HIS GLN PHE PHE LYS THR SER GLY LYS MET GLY PRO GLY SEQRES 16 A 576 PHE THR LYS ALA LEU GLY HIS GLY VAL ASP LEU GLY HIS SEQRES 17 A 576 ILE TYR GLY ASP ASN LEU GLU ARG GLN TYR GLN LEU ARG SEQRES 18 A 576 LEU PHE LYS ASP GLY LYS LEU LYS TYR GLN MET LEU ASN SEQRES 19 A 576 GLY GLU VAL TYR PRO PRO SER VAL GLU GLU ALA PRO VAL SEQRES 20 A 576 LEU MET HIS TYR PRO ARG GLY ILE PRO PRO GLN SER GLN SEQRES 21 A 576 MET ALA VAL GLY GLN GLU VAL PHE GLY LEU LEU PRO GLY SEQRES 22 A 576 LEU MET LEU TYR ALA THR ILE TRP LEU ARG GLU HIS ASN SEQRES 23 A 576 ARG VAL CYS ASP LEU LEU LYS ALA GLU HIS PRO THR TRP SEQRES 24 A 576 GLY ASP GLU GLN LEU PHE GLN THR ALA ARG LEU ILE LEU SEQRES 25 A 576 ILE GLY GLU THR ILE LYS ILE VAL ILE GLU GLU TYR VAL SEQRES 26 A 576 GLN GLN LEU SER GLY TYR PHE LEU GLN LEU LYS PHE ASP SEQRES 27 A 576 PRO GLU LEU LEU PHE GLY ALA GLN PHE GLN TYR ARG ASN SEQRES 28 A 576 ARG ILE ALA MET GLU PHE ASN GLN LEU TYR HIS TRP HIS SEQRES 29 A 576 PRO LEU MET PRO ASP SER PHE ARG VAL GLY PRO GLN ASP SEQRES 30 A 576 TYR SER TYR GLU GLN PHE LEU PHE ASN THR SER MET LEU SEQRES 31 A 576 VAL ASP TYR GLY VAL GLU ALA LEU VAL ASP ALA PHE SER SEQRES 32 A 576 ARG GLN PRO ALA GLY ARG ILE GLY GLY GLY ARG ASN ILE SEQRES 33 A 576 ASP HIS HIS ILE LEU HIS VAL ALA VAL ASP VAL ILE LYS SEQRES 34 A 576 GLU SER ARG VAL LEU ARG LEU GLN PRO PHE ASN GLU TYR SEQRES 35 A 576 ARG LYS ARG PHE GLY MET LYS PRO TYR THR SER PHE GLN SEQRES 36 A 576 GLU LEU THR GLY GLU LYS GLU MET ALA ALA GLU LEU GLU SEQRES 37 A 576 GLU LEU TYR GLY ASP ILE ASP ALA LEU GLU PHE TYR PRO SEQRES 38 A 576 GLY LEU LEU LEU GLU LYS CYS HIS PRO ASN SER ILE PHE SEQRES 39 A 576 GLY GLU SER MET ILE GLU MET GLY ALA PRO PHE SER LEU SEQRES 40 A 576 LYS GLY LEU LEU GLY ASN PRO ILE CYS SER PRO GLU TYR SEQRES 41 A 576 TRP LYS ALA SER THR PHE GLY GLY GLU VAL GLY PHE ASN SEQRES 42 A 576 LEU VAL LYS THR ALA THR LEU LYS LYS LEU VAL CYS LEU SEQRES 43 A 576 ASN THR LYS THR CYS PRO TYR VAL SER PHE HIS VAL PRO SEQRES 44 A 576 ASP PRO ARG GLN GLU ASP ARG PRO GLY VAL GLU ARG PRO SEQRES 45 A 576 PRO THR GLU LEU

MODRES 1DJJ ASN A 68 ASN GLYCOSYLATION SITE MODRES 1DJJ ASN A 144 ASN GLYCOSYLATION SITE MODRES 1DJJ ASN A 410 ASN GLYCOSYLATION SITE

FTNOTE 1 CIS PROLINE - PRO 127

HET NAG A 661 28 HET NAG A 671 27 HET NAG A 672 28 HET NAG A 681 28 HET BOG 702 48 HET HEM 601 79 HET NSA 0 19

HETNAM NAG N-ACETYL-D-GLUCOSAMINE HETNAM BOG B-OCTYLGLUCOSIDE HETNAM HEM PROTOPORPHYRIN IX CONTAINING FE HETNAM NSA 2,2-DICHLORO-N-PHENYL-ACETAMIDE

HETSYN NAG NAG HETSYN HEM HEME

FORMUL 2 NAG 4(C8 H15 N O6) FORMUL 5 BOG C14 H28 O6 FORMUL 6 HEM C34 H32 FE N4 O4 FORMUL 7 NSA C8 H7 CL2 N O FORMUL 8 HOH *(H2 O1)

HELIX 1 1 ASN A 34 TYR A 39 5 6 HELIX 2 2 CYS A 41 GLY A 45 5 5 HELIX 3 3 GLU A 73 ARG A 83 1 11 HELIX 4 4 SER A 85 HIS A 95 1 11 HELIX 5 5 GLY A 96 ALA A 105 1 10 HELIX 6 6 PHE A 107 ASN A 122 1 16 HELIX 7 7 TRP A 139 ASN A 144 1 6 HELIX 8 8 ASP A 173 LEU A 182 1 10 HELIX 9 9 ASN A 195 HIS A 207 1 13 HELIX 10 10 LEU A 230 GLY A 235 1 6 HELIX 11 11 ASN A 237 ARG A 245 1 9 HELIX 12 12 PRO A 280 GLN A 284 5 5 HELIX 13 13 GLN A 289 LEU A 294 5 6 HELIX 14 14 LEU A 295 HIS A 320 1 26 HELIX 15 15 GLY A 324 GLU A 347 1 24 HELIX 16 16 GLU A 347 GLY A 354 1 8 HELIX 17 17 ASP A 362 PHE A 367 5 6 HELIX 18 18 ALA A 378 HIS A 386 1 9 HELIX 19 19 TRP A 387 MET A 391 5 5 HELIX 20 20 SER A 403 PHE A 407 5 5 HELIX 21 21 SER A 412 GLY A 418 1 7 HELIX 22 22 GLY A 418 GLN A 429 1 12 HELIX 23 23 ASP A 441 HIS A 443 5 3 HELIX 24 24 ILE A 444 LEU A 458 1 15 HELIX 25 25 PRO A 462 PHE A 470 1 9 HELIX 26 26 SER A 477 THR A 482 1 6 HELIX 27 27 LYS A 485 GLY A 496 1 12 HELIX 28 28 ASP A 497 LEU A 501 5 5 HELIX 29 29 GLU A 502 LEU A 509 1 8 HELIX 30 30 GLY A 519 GLY A 536 1 18 HELIX 31 31 ASN A 537 SER A 541 5 5 HELIX 32 32 GLY A 552 THR A 561 1 10 HELIX 33 33 THR A 563 LEU A 570 1 8

SHEET 1 A 2 ILE A 46 ARG A 49 0 SHEET 2 A 2 TYR A 55 ASP A 58 -1 N GLN A 56 O VAL A 48 SHEET 1 B 2 TYR A 64 SER A 65 0 SHEET 2 B 2 ILE A 71 PRO A 72 -1 N ILE A 71 O SER A 65 SHEET 1 C 2 TYR A 130 ASN A 131 0 SHEET 2 C 2 THR A 149 ARG A 150 -1 N ARG A 150 O TYR A 130 SHEET 1 D 2 GLN A 255 LEU A 257 0 SHEET 2 D 2 GLU A 260 TYR A 262 -1 N GLU A 260 O LEU A 257 SHEET 1 E 2 PHE A 395 VAL A 397 0 SHEET 2 E 2 GLN A 400 TYR A 402 -1 O GLN A 400 N VAL A 397

SSBOND 1 CYS A 36 CYS A 47 SSBOND 2 CYS A 37 CYS A 159 SSBOND 3 CYS A 41 CYS A 57 SSBOND 4 CYS A 59 CYS A 69 SSBOND 5 CYS A 569 CYS A 575

LINK O4 NAG A 671 C1 NAG A 672 LINK ND2 ASN A 68 C1 NAG A 661 LINK ND2 ASN A 144 C1 NAG A 671 LINK ND2 ASN A 410 C1 NAG A 681

CISPEP 1 SER A 126 PRO A 127 0 5.38

CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1

ORIGX1 1.000000 0.000000 0.000000 0.00000

ORIGX2 0.000000 1.000000 0.000000 0.00000

ORIGX3 0.000000 0.000000 1.000000 0.00000

SCALE1 0.010043 0.000000 0.000000 0.00000

SCALE2 0.000000 0.004766 0.000000 0.00000

SCALE3 0.000000 0.000000 0.004255 0.00000